Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20847509 | 0.95 | HDAC6 (0.67) | HDAC6HDAC8HDAC11HDAC3MEN1 | |
| SCHEMBL20839241 | 0.85 | HDAC6 (0.76) | HDAC6HDAC8HDAC11HDAC3MEN1 | |
| SCHEMBL22482909 | 0.84 | HDAC6 (1.00) | HDAC6HDAC8HDAC11HDAC3 | |
| SCHEMBL20847479 | 0.84 | HDAC6 (0.74) | HDAC6HDAC8HDAC11HDAC3MEN1 | |
| SCHEMBL20847784 | 0.83 | HDAC6 (0.63) | HDAC6HDAC8HDAC11HDAC3MEN1 | |
| SCHEMBL20847546 | 0.83 | HDAC6 (0.61) | HDAC6HDAC8HDAC11HDAC3MEN1 | |
| SCHEMBL20847554 | 0.81 | HDAC6 (0.69) | HDAC6HDAC8HDAC11HDAC3MEN1 | |
| SCHEMBL20847550 | 0.81 | HDAC6 (0.68) | HDAC6HDAC8HDAC11HDAC3MEN1 | |
| SCHEMBL14842844 | 0.80 | MEN1 (0.76) | HDAC6HDAC8HDAC3MEN1KMT2A | |
| SCHEMBL20847603 | 0.78 | HDAC6 (0.65) | HDAC6HDAC8HDAC11HDAC3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277268-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2020-09-03 | — | — | US | disclosed |
| WO-2019056120-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277268-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKI67, PKD1, ETV6 | HDAC6 499/4885HDAC8 1916/4885HDAC11 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.